Evaluating Sunitinib for Advanced and Metastatic Pheochromocytomas and Paragangliomas: Efficacy, Safety, and Clinical Implications from Prospective Trials
This meta-analysis synthesizes prospective data on sunitinib treatment in metastatic pheochromocytomas and paragangliomas, revealing modest response rates and meaningful disease control with manageable safety profiles.